/
Cardiff Oncology, Inc.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Mentions
1 mention · latest on 5 Apr 2026
See which tracked investors hold Cardiff Oncology, Inc. →Ownership and position changes on OwnershipTrace